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Abstract
Background: Setting lactate kinetics at >30% might improve the clinical outcomes of patients with sepsis-
associated hyperlactatemia. The aim of this study was to explore the outcome benefits of stepwise lactate kinetics
vs central venous oxygen saturation (ScvO2)-oriented hemodynamic therapy at 6 h as the protocol goal during
early resuscitation.
Methods: The relevant parameters and adverse events after different targets in 360 randomly assigned patients
with sepsis-associated hyperlactatemia were recorded and compared.
Results: Heart rate (HR) at 48 h in the ScvO2 group was higher than in the lactate kinetics group (105 ± 19 bpm vs
99 ± 20 bpm, P = 0.040). The liquid balance at 4 h, 12 h, and 24 h in the lactate kinetics group was larger than in
the ScvO2 group (1535 (1271–1778) ml vs 826 (631–1219) ml, P < 0.001; 1688 (1173–1923) ml vs 1277 (962 − 1588)
ml, P <0.001; and 1510 (904–2087) ml vs 1236 (740–1808) ml, P = 0.005), respectively. Mortality was higher in the
ScvO2 group (27.9% vs 18.3%, P = 0.033), but there was no significant difference between the two groups in the
length of stay in the ICU or mechanical ventilation. In terms of new onset organ dysfunction, there was a significant
difference between the two groups in total bilirubin at 48 h and 72 h. Based on the 60-day survival curves, there
was significantly more mortality in the ScvO2 group than in the lactate kinetics group (X
2 = 4.133, P = 0.042). In
addition, fewer adverse events occurred in the lactate kinetics group.
Conclusions: Stepwise lactate kinetics-oriented hemodynamic therapy can reduce mortality in patients with sepsis-
associated hyperlactatemia compared with ScvO2-oriented therapy.
Trial registration: National Institutes of Health Clinical Trials Registry, NCT02566460. Registered on 26
September 2015.
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Background
Morbidity due to sepsis affects 56–91 people per 100,000/
year, and the associated mortality remains at approxi-
mately 20% or even higher [1–3]. Early goal-directed ther-
apy (EGDT) in the treatment of severe sepsis and septic
shock strategies suggested by Rivers et al. in 2001 have
had a far-reaching impact on the resuscitation of patients
with severe sepsis or septic shock [4]. The EGDT
strategies have been recognized and recommended by the
Surviving Sepsis Campaign (SSC) since 2002 as the core
concept of the SSC guidelines [5–7], with profound
impacts on the behavior of physicians in critical care
medicine worldwide.
However, recently, with the results of the ProCESS,
ARISE and ProMISe trials having been published, clini-
cians have begun to doubt central venous oxygen satur-
ation (ScvO2) as an important objective of EGDT
during the resuscitation of patients with sepsis [8–10].
Lactate, as a product of the anaerobic metabolism of
tissue, is considered closer to the real situation of poor
tissue perfusion. In recent years, some studies have
noted that lactate kinetics could predict the prognoses
of patients with severe sepsis [11–15]. In an observa-
tional study Nguyen et al. reported that lactate kinetics
of 10% might indicate a better prognosis in patients with
sepsis, and that every 10% increase in lactate kinetics
over 6 h could further reduce mortality [12].
The EMShockNet investigators performed a multicenter,
randomized non-inferiority trial and demonstrated that
there was no significant difference in mortality among
patients with sepsis when they used lactate kinetics greater
than 10% in 6 h, compared with ScvO2 ≥ 70% [14]. by Craig
et al. found in a retrospective study that 36% lactate kinetics
in 6 h could be used as a prognostic cutoff value [15]. We
presumed that the reason why the superiority of lactate kin-
etics was not demonstrated might be that the target lactate
kinetics was not set sufficiently high. Therefore, we set the
target thresholds of lactate kinetics at 2 h up to 10%, 4 h up
to 20%, and 6 h up to at least 30%, and we defined it as
stepwise lactate kinetics-oriented hemodynamic therapy.
We designed a single-center, randomized controlled study
to assess stepwise lactate kinetics-oriented vs ScvO2-ori-
ented hemodynamic therapy in early 6-h resuscitation
among patients with sepsis-associated hyperlactatemia in
terms of the benefits for outcome.
Methods
Study design and patient enrollment
The trial was performed in the Critical Care Department
of Peking Union Medical College Hospital in China.
Patients with sepsis-associated hyperlactatemia admitted
to the hospital from January 2013 to December 2014
were enrolled. The research protocol was reviewed and
approved by the Ethics Committee of Peking Union
Medical College Hospital (PUMCH-S616) and was regis-
tered in the U.S. National Institutes of Health Clinical
Trials Registry (NCT 02566460).
Patients were assessed according to inclusion criteria,
which required that the patients be older than 18 years
of age with confirmed or presumed infection, that they
met two or more criteria for systemic inflammatory re-
sponse syndrome [5–7, 16] and that there was evidence
of refractory hypotension or serum lactate greater than
4 mmol per liter. Refractory hypotension was defined as
systolic blood pressure below 90 mm Hg or mean arter-
ial pressure (MAP) below 65 mm Hg after an intraven-
ous fluid challenge of 20 ml or more per kilogram of
body weight. Patients had to be enrolled in the study
within 2 h of the earliest detection of the inclusion cri-
teria and within 1 h of arrival in the ICU.
Patients were excluded if they met any of the following
criteria: age younger than 18 years, pregnancy, an acute
cerebral vascular event (Glasgow coma score <5), acute
myocardial infarction or acute coronary syndrome,
massive pulmonary embolism, status asthmaticus, pri-
mary diagnosed cardiac dysrhythmia, contraindication to
central venous catheterization, active gastrointestinal
hemorrhage, massive intra-abdominal infective focus
without drainage, severe bronchopleural fistula, seizure,
receiving chemotherapy or immunosuppressive therapy,
or in the end stage of a disease. Non-inferiority testing
was adopted in this study. Based on ScvO2, the mortality
rate was approximately 25%, so α was set at 0.05, 1-β
was set at 0.9, the non-inferiority value was 0.15, and the
calculated sample size was 175 in each group.
Randomization was performed with the use of a random
number table. All of the patients or their legally autho-
rized representatives provided written informed consent.
Treatment
Eligible patients were randomly assigned in a 1:1 ratio to
one of the two groups: the protocol-based lactate kinet-
ics group or the protocol-based ScvO2 group. When
these patients were admitted to the ICU, they were re-
ferred to a single critical care physician, who was
assigned as the research investigator. Routine procedures
for the treatment of shock in the ICU, such as intratra-
cheal intubation and central venous catheterization with
the tip of the catheter located in the superior vena cava,
were performed. Central venous pressure (CVP) was
measured continuously using a bedside monitor. Antibi-
otics were administered intravenously at the discretion
of the attending clinician. After the baseline measure-
ments, the patients were randomized into one of the
two groups by opening an opaque, sealed envelope
containing the randomization assignment.
Patients assigned to the ScvO2 group received chest or
neck central venous catheterization capable of measuring
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continuous ScvO2 (Edwards Lifesciences, Irvine, CA,
USA). Then, the patients were resuscitated following the
EGDT protocol, which was used by Rivers et al. [4]. The
protocol provides for sequential resuscitation to meet the
thresholds of central venous pressure, followed by MAP
and then ScvO2 within the first 6 h of ICU admission.
First, either crystalloid or colloid could be administered to
achieve a CVP of 8 − 12 mmHg. Second, if the MAP was
below 65 mm Hg, norepinephrine was administered to
maintain MAP ≥65 mmHg. If the MAP was above 90 mm
Hg, vasodilators were administered until it was 90 mm Hg
or lower. Finally, if ScvO2 was below 70%, red blood cells
were transfused to achieve a hematocrit of at least 30%. If
ScvO2 continued to be below 70%, dobutamine was initi-
ated and titrated in attempts to achieve ScvO2 of at least
70%.
Patients assigned to the lactate kinetics group were
treated according to the protocol of lactate kinetics-
oriented therapy within the first 6 h of ICU admission.
All of the patients in this group also accepted with cen-
tral venous catheterization to monitor CVP, but they did
not have ScvO2 monitored. They had similarly targeted
thresholds in CVP, followed by MAP. However, blood
lactate in the lactate kinetics group was monitored at a
minimum of 1-h intervals:
Lactate kinetics ¼ Lactateinitial − Lactatetimeð Þ
Lactateinitial
100%:
Lactateinitial was the blood lactate level when the pa-
tients were included in the study; lactatetime was the
blood lactate level measured at relevant time points. We
set the target thresholds of lactate kinetics at 2 h up to
10%, 4 h up to 20%, and 6 h up to at least 30%. After the
lactate kinetics group achieved the resuscitation goals of
CVP and MAP, if the lactate kinetics rate had not
reached the intended target at the corresponding time
point, red blood cells were transfused to achieve a
hematocrit of at least 30%. If the lactate kinetics remained
below the intended target at the corresponding time point
after the hematocrit was at least 30%, dobutamine was initi-
ated and titrated, in an attempt to achieve the target value.
Lactate measurements were performed on venous whole
blood samples using a blood gas analyzer (ABL90 FLEX,
Radomater Medical, Copenhagen, Denmark).
After the 6 h of early intervention, the two groups
continued to be observed at 12, 24, 48, and 72 h, and
using the same treatment strategies. In addition to the
hemodynamic treatment mentioned, a series of sepsis
treatments based on the 2012 SCC guidelines were per-
formed, including eliminating the foci, using antibiotics
early, providing low-dose glucocorticoids, and control-
ling blood sugar.
To ensure patient safety, the study allowed the phys-
ician in charge to decide to adjust the treatment of pa-
tients according to the clinical situation. For example, in
the ScvO2 group, the doctor in charge could decide at
some point to check the patient’s lactate and calculate
the lactate clearance rate. In the lactate kinetics group,
physicians could also decide at some point to start
ScvO2 monitoring. However, these patients had to meet
the following conditions for at least one item: (1) systolic
blood pressure (SBP) was difficult to maintain (SBP
<90 mmHg) or decreased urine output (<0.5 ml/kg per h);
(2) respiratory conditions continued to worsen (including
respiratory rate, oxygen saturation or oxygen require-
ment), and arterial blood gas or mechanical ventilation
conditions continued to deteriorate; or (3) consciousness
continued to deteriorate. Once patients received the treat-
ment of the other group, he or she was also considered to
be included due to intention-to-treat selection.
Outcome measurements
After the patients’ enrollment, case report forms (CRFs)
were completed by the attending physicians according to
the protocols. The primary endpoint was 60-day mortal-
ity. The secondary end points were ICU and hospital
length of stay, ventilator-free days, and newly emerging
organ failure. Other end points included the number of
protocol goals achieved, administered treatments, and
protocol-related adverse events. The protocol-related
data were collected at baseline, at each hour for 6 h and
then at 24, 48, and 72 h. All of the patients were
followed up until 60 days. The protocol implementation
and data collection stopped when the patients or their
families wished to withdraw from the program or
refused further treatment, or if the patient died.
Statistical analysis
The data were analyzed using intention-to-treat principles.
The count data were analyzed using the chi-square test or
Fisher's exact method; for measurement data, if the two
sets of data did not follow a normal distribution, they were
described by medians (interquartile ranges), and we used
the Mann-Whitney U test to compare the two groups. If
they had a normal distribution, mean ± standard deviation
was used, and the independent sample t test was adopted
to compare the two groups. Sixty-day survival curves were
plotted, and the mortality rates in both groups were
analyzed using the Breslow survival test. All of the data
analyses were performed using SAS software, version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
Between January 2013 and December 2014, a total of
420 patients with sepsis met the inclusion criteria.
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Among these patients, 12 met the exclusion criterion,
and 48 refused to participate in this study. Finally, 360
eligible patients were randomized into the lactate kinet-
ics group (n = 180) and the ScvO2 group (n = 180).
Among the 180 patients in the lactate kinetics group, an
internal jugular or subclavian catheter could not be
inserted in 2 patients, the original plan was not imple-
mented in 7 patients during the trial, and 19 patients did
not meet the planned target, despite the protocol having
been strictly followed. Among the 180 patients in the
ScvO2 group, a jugular or subclavian catheter could not
be inserted in 1 patient, 5 patients did not have the ori-
ginal plan implemented, and 15 patients did not meet
the original plan (Fig. 1).
There were no significant differences between the two
groups in the baseline data. The sites of infection in the
two groups all indicated that pulmonary infection (48.3%
vs 47.7%, P = 0.916), severity of illness (APACHE II score
18 (14–30) vs 20 (14–31), P = 0.512), organ function
(alanine aminotransferase (ALT), total bilirubin (TBIL),
serum creatinine (SCr), and troponin (Tni)) and
hemodynamic status (HR, MAP, CVP, lactate) did not
differ significantly (Table 1).
Treatment and vital signs
Of the 180 patients in the ScvO2 group, 5 required other
indicators, such as lactate, to guide the clinical interven-
tion. Therefore, the original plan was not implemented
in these patients. The 6-h ScvO2 compliance rate was
98.9%. The average ScvO2 in the two groups was 77.7 ±
9.5%. Of the 180 patients in the lactate kinetics group, 7
required other indicators, such as ScvO2, to guide the
clinical intervention. We recalculated the target achieve-
ment rate. The 2-h lactate kinetics target rate was met
and the compliance rate above 10% was 83.9%; the 4-h
lactate kinetics rate was 87.2%; and the 6-h target rate
was 80.6%. The time course of ScvO2 in the ScvO2
group and lactate in the lactate kinetics group are shown
as Additional file 1: Table S1.
There were no significant differences between the lac-
tate kinetics and ScvO2 groups in the use of vasoactive
drugs, inotropic drugs, or red blood cells. At 4 h, 12 h,
and 24 h, more intravenous fluids were administered in
the lactate kinetics group than in the ScvO2 group, with
1535 (1271–1778) ml vs 826 (631–1219) ml (P = 0.000),
1688 (1173–1923) ml vs 1277 (962–1588) ml (P = 0.000),
and 1510 (904–2087) ml vs 1236 (740–1808) ml (P =
Fig. 1 The flowchart of the enrollment of this study. ScvO2 central venous oxygen saturation
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0.005), respectively (Table 2). There was no significant
difference in the hemodynamic monitoring data for
MAP, but HR in the ScvO2 group was higher at 48 h
than in the lactate kinetics group (105 ± 19 bpm vs 99 ±
20 bpm, P = 0.040). CVP at 4 h, 6 h, and 12 h was
greater in the lactate kinetics group than in the ScvO2
group (8 (6–10) mmHg vs 7 (5–9) mm Hg, P = 0.039; 9
(6–13) mmHg vs 8 (5–11) mmHg, P = 0.027; and 9 (7–11)
mmHg vs 8 (6–10) mmHg, P = 0.041, respectively).
Primary and secondary outcomes
Sixty-day mortality was higher in the ScvO2 group than
in the lactate kinetics group (27.9% vs 18.3%, P = 0.033),
but there was no significant difference between the two
groups in the duration of mechanical ventilation while
on the ICU. In terms of new onset of organ dysfunction,
there was no significant difference in impairment of
renal function in the lactate kinetics group compared
with the ScvO2 group. There were significant differences
in TBIL between the two groups at 48 h and 72 h
(Table 3). Based on the 60-day survival curves, mortality
was greater in the ScvO2 group than in the lactate kinet-
ics group, with significant differences after Breslow test-
ing (X2 = 4.133, P = 0.042) (Fig. 2).
Adverse events
Equal numbers of adverse events occurred in the two
groups (Table 4). There were adverse events in four
cases in the lactate kinetics group (2.2%), while in the
ScvO2 group there were adverse events in 5 cases (2.8%).
There was no statistically significant difference between
the two groups (P = 1.000). Adverse events in the lactate
kinetics group included one case of acute pulmonary
edema, two cases of cardiac arrhythmia, and one case of
catheter-related infections, while the adverse events in
the ScvO2 group included one case of acute pulmonary
edema, one case of acute myocardial infarction, and
three cases of arrhythmia.
Table 1 The baseline data for patients with septic shock who were enrolled in this study
Lactate kinetics group ScvO2 group P value
n = 180 n = 180
Sex, male/female, n 95/85 106/74 0.289
Age, years 56 (44–66) 56 (40–67) 0.455
APACHE II score 18 (14–30) 20 (14–31) 0.512
WBC counts, ×10^9/L 12.9 (8.4–17.9) 12.0 (8.4–17.3) 0.957
Hemoglobin, g/L 101 (86–117) 105 (85–119) 0.217
Platelets, ×10^9/L 143 (85–191) 125 (74–196) 0.798
PT, s 15.4 (13.3–18.0) 15.1 (13.0–17.7) 0.547
APTT, s 36.2 (28.8–51.9) 35.6 (29.4–51.1) 0.519
ALT, U/L 106.0 (53.5–156.5) 78.0 (46.0–142.0) 0.161
TBIL, mmol/L 19.5 (11.6–37.2) 18.1 (10.7–41.9) 0.807
Albumin, g/L 27 (22–30) 27 (23–31) 0.109
sCR, mmol/dL 91.5 (65.3–163.5) 102 (65.5–182.5) 0.484
cTnI, mg/L) 0.42 (0.04–3.40) 0.29 (0.05–2.97) 0.635
HR, bpm 109 ± 25 114 ± 28 0.184
MAP, mmHg 83 (72–93) 87 (76–100) 0.113
Arterial lactate, mmol/L 5.8 (4.4–8.7) 5.6 (4.3–8.1) 0.156
Site of infection
Lung, n 87 86 0.916
Intraperitoneal, n 58 60 0.822
Urinary system, n 1 1 1
Biliary tract infection, n 8 10 0.629
Skin and soft tissue, n 9 6 0.435
Blood infection, n 9 7 0.609
Other, n 8 10 0.629
ScvO2 central venous oxygen saturation, APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood cells, PT prothrombin time, APTT activated
partial thromboplastin time, ALT alanine transaminase, TBIL total bilirubin, sCR serum creatinine, cTnI cardiac troponin I, HR heart rate, MAP mean arterial pressure
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Discussion
The main finding of this randomized, controlled trial
was that stepwise lactate kinetics-oriented hemodynamic
therapy could reduce mortality among patients with
sepsis-associated hyperlactatemia, compared with
ScvO2-oriented therapy. The therapeutic targets were
reached in most patients during the first 6 h, which
could indicate that the protocols were easily accepted
and implemented. The lactate kinetics group had more
fluid within the first 24 h, especially at 4 h, 12 h, and
24 h, but there were no differences between the two
groups at 48 h or 72 h. The lactate kinetics group had a
lower heart rate and less norepinephrine than the ScvO2
group, especially at 48 h. However, there was no differ-
ence in CVP between the two groups. More patients re-
quired dobutamine in the lactate kinetics group than in
the ScvO2 group, but the difference was not significant.
In addition, there was no difference in adverse events
between these two groups.
An optimal resuscitation strategy for sepsis patients
should have two characteristics: (1) it should be able to
generate sufficient driving force for the specific clinical
treatment so that it can better guide the clinical therapy,
and (2) it should also be able to achieve effective resusci-
tation while avoiding overtreatment. The strategy rec-
ommended by EGDT [4] and the SSC bundles [2] has
two central points – CVP and MAP, respectively – and
the end point is ScvO2. This strategy was very clear in
outlining the clinical path of resuscitation in patients
with sepsis, and it has been widely accepted and pro-
moted over the past 10 years.
The IMPreSS study group demonstrated that compli-
ance with SSC bundles was independently associated
with improvements in hospital mortality among patients
Table 2 Interventions in the ScvO2-oriented group and lactate kinetics-oriented group during the treatment process
Lactate kinetics group ScvO2 group P value
n = 180 n = 180
RBC volume at 24 h, ml 144 ± 192 152 ± 193 0.705
Norepinephrine, %
1st day 46.1% (83/180) 46.7% (84/180) 0.916
2nd day 38.9% (70/180) 40.6% (73/180) 0.747
3rd day 27.2% (49/180) 30.3% (54/180) 0.560
Norepinephrine, μg/kg/h
0 (0–4.46) 0 (0–7.75) 0.843
0 (0–3.67) 0 (0–7.19) 0.1
0 (0–0.57) 0 (0–2.45) 0.272
Dobutamine, %
1st day 2.2% (4/180) 3.9% (7/180) 0.358
2nd day 4.4% (8/180) 3.3% (6/180) 0.586
3rd day 3.9% (7/180) 3.3% (6/180) 0.778
Dobutamine, μg/kg/h
1st day 0 (0–0) 0 (0–0) 0.325
2nd day 0 (0–0) 0 (0–0) 0.263
3rd day 0 (0–0) 0 (0–0) 0.618
CVVH 26/154 36/144 0.163
Fluid volume, ml
0–2 h 563 (259–922) 590 (288–960) 0.539
2–4 h 1535 (1271–1778) 826 (631–1219) <0.001
4–6 h 1687 (1476–1929) 1255 (1008–1537) 0.358
6–12 h 1688 (1173–1923) 1277 (962–1588) <0.001
12–24 h 1510 (904–2087) 1236 (740–1808) 0.005
24–48 h 465 (341–606) 424 (279–552) 0.071
48–72 h 278 (159–410) 284 (226–324) 0.502
ScvO2 central venous oxygen saturation, CVVH continuous veno-venous hemofiltration
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with sepsis [17]. Since ProCESS, ARISE, and ProMISe
were published, the EGDT strategy in sepsis resuscita-
tion has once again aroused great controversy [8–10].
All three of these studies demonstrated that protocols
using ScvO2 as a resuscitation goal do not offer a sur-
vival advantage in patients with early septic shock.
Table 3 Primary and secondary clinical outcomes in the ScvO2-oriented group and lactate kinetics-oriented group




n = 180 n = 180
Mortality at 60 days 33 (18.3%) 50 (27.9%) 0.033
Mechanical ventilation time, h 25 (14–97) 35 (16–106) 0.465
ICU stay time, h 68 (24–138) 66 (27–166) 0.348
Organ dysfunction
Alanine aminotransferase, g/L
0 h 106.0 (53.5–156.5) 78.0 (46.0–142.0) 0.161
24 h 125.0 (74.0–177.0) 118 (62.8–186.8) 0.844
48 h 114 (73.0–157) 109 (67–150) 0.47
72 h 113 (72–160.8) 109 (74–161.5) 0.725
Total bilirubin, mmol/L
0 h 19.5 (11.6–37.2) 18.1 (10.7–41.9) 0.807
24 h 17.7 (11.7–32.4) 17.8 (10.7–38.7) 0.843
48 h 21.4 (13.3–35.5) 21.0 (12.6–50.8) 0.564
72 h 20.3 (13.1–33.7) 19.0 (11.8–40.2) 0.865
Serum creatinine, μmol/L
0 h 91.5(65.3–163.5) 102(65.5–182.5) 0.484
24 h 79(59.0–128) 80(62.0–130) 0.443
48 h 81(58–117) 83(63.2–139.8) 0.217
72 h 72.5(53.8–111.5) 76(58–141) 0.123
Cardiac troponin I, μg/L
0 h 0.42 (0.04–3.40) 0.29 (0.05–2.97) 0.635
24 h 0.14 (0.016–2.12) 0.12 (0.02–1.52) 0.766
48 h 0.30 (0.02–2.46) 0.21 (0.04–2.79) 0.745
72 h 0.19 (0.01–1.74) 0.15 (0.03–1.67) 0.61
Hemodynamic parameters
Heart rate, beats per minute
0 h 109 ± 25 114 ± 28 0.184
24 h 107 ± 24 112 ± 23 0.183
48 h 99 ± 20 105 ± 19 0.04
72 h 96 ± 24 99 ± 17 0.467
Mean arterial pressure, mmHg
0 h 83(72–93) 87(76–100) 0.113
24 h 86 (74–96) 88 (75–99) 0.712
48 h 88 ± 15 85 ± 18 0.37
72 h 91 ± 12 87 ± 15 0.111
Central venous pressure, mmHg
0 h 7 (5–8) 7 (6–8) 0.866
2 h 8 (6–10) 8 (7–10) 0.573
4 h 8 (6–10) 7 (5–9) 0.039
6 h 9 (6–13) 8 (5–11) 0.027
12 h 9 (7–11) 8 (6–10) 0.041
24 h 9 (7–11) 8.5 (7–11) 0.695
48 h 9 (7.3–10) 9 (7–10) 0.901
72 h 8 (6.3–10) 8 (6–9.7) 0.064
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However, many researchers have assumed that the low
mortality in the usual-care groups in the three studies
might have been due to these patients receiving pre-
existing protocol-driven care, as outlined in the SSC
bundles [18, 19]. In fact, any treatment in clinical prac-
tice must have a clear goal to be reached. The core of
the dispute is not the validity of goal-directed therapy
strategies but the question as to whether ScvO2 is the
proper goal to guide early sepsis resuscitation.
The average enrollment ScvO2 levels, which were de-
fined as the average levels when the patients were en-
rolled, were very different in the study of Rivers et al.
compared to more recent studies, including our own.
The average enrollment ScvO2 was 49% in the study of
Rivers et al. However, the average enrollment ScvO2
levels in ProCESS, ARISE, and ProMISe were 71%,
72.7%, and 70%, respectively, while in our study, it was
72.1% [8–10]. This discrepancy is one of the most im-
portant differences between the study of Rivers et al. and
our study, indicating that there was quite a large propor-
tion of patients in the ScvO2 group who could not re-
ceive future resuscitation according to the protocols in
these studies (approximately 69% of the patients in our
study). In fact, Rivers et al. also reported that low ScvO2
usually indicates inadequate oxygen delivery or excessive
oxygen consumption, but high ScvO2 did not exclude
hypoperfusion in their study [4]. Pope and Textoris re-
ported that not only did low ScvO2 suggest poor prog-
nosis but that high ScvO2 was also associated with poor
prognosis in patients with sepsis [20, 21]. Thus, it could
be that ScvO2-oriented therapy could not promote re-
suscitation in more than 50% of patients with sepsis and
could not prevent overtreatment.
Fig. 2 The 60-day survival curves in the central venous oxygen saturation (ScvO2)-oriented group and lactate kinetics-oriented group
Table 4 The adverse event statistics in the ScvO2-oriented






n = 180 n = 180
Total number of adverse
events, n/%
4/2.2% 5/2.8% >0.05
Acute pulmonary edema, n 1 1
Acute myocardial infarction, n 0 1
Arrhythmia, n 2 3
Cardiac arrest, n 0 0
Pneumothorax caused
by the puncture, n
0 0




ScvO2 central venous oxygen saturation, RBC red blood cells
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It has been widely accepted that initial hyperlactacide-
mia is associated with greater mortality in patients with
sepsis, and it has been regarded as independent of other
organ failure indicators [11, 22–25]. Lactate kinetics and
its kinetics, which reflect the dynamic changes in blood
lactate, might more accurately reflect the quality of
shock resuscitation and could predict the prognosis of
patients better than many other methods that consist
purely of fixed measurements of hemodynamic parame-
ters [11–14]. Therefore, we believe that lactate kinetics
and its kinetics is a good endpoint of goal-directed
therapy for resuscitation in patients with sepsis. How-
ever, the optimal cutoff value for lactate kinetics to guide
resuscitation in sepsis is controversial. In clinical situa-
tions, any treatment to improve tissue perfusion (includ-
ing increasing oxygen delivery (DO2) or decreasing
oxygen consumption (VO2)) can reduce blood lactate
levels to a certain extent, that is, the inherent ability that
reflects the effects of recovery during the resuscitation
process. Therefore, an optimal lactate kinetics threshold
must be sufficiently high to produce a driving force to
propel the resuscitation strategy forward.
To date, lactate kinetics has been as the endpoint
of goal-directed therapy in the resuscitation of pa-
tients with sepsis in three randomized, controlled
clinical trials. The EMShockNet investigators reported
non-inferiority in terms of reduction in hospital mor-
tality among the group with lactate kinetics greater
than 10% at 6 h and in the group with ScvO2 ≥ 70%
at 6 h (17% vs 23%) [15]. Jansen et al. reported that
hospital mortality in the lactate kinetics group
reaching 20% every 2 h was not different compared
with the conventional treatment group (33.9% vs
43.5%, P = 0.067) [24]. Tian et al. compared the re-
sults of 28-day mortality between lactate kinetics
greater than,, 10% and 30%, respectively at 6 h and
ScvO2 > 70%. The results were significantly lower in
the 30% lactate kinetics group (28.6%) and the 10%
group (36.4%) than in the ScvO2 group (63.2%) (P <
0.05) [25]. However, this study included only 62 cases,
and 28-day mortality in the ScvO2 group was much higher
than that in the present study (63.2%.), while Craig et al.
reported in a retrospective study that resuscitation within
6 h and lactate kinetics of 36% could forecast the progno-
ses of patients with sepsis, and the cutoff value was set at
36% [14]. Therefore, in our goal-directed therapy protocol,
after CVP and MAP reached the targets, based on the
existing research results, the target lactate kinetics was set
at 10%, 20%, and 30% at 2 h, 4 h, and 6 h, respectively.
This stepwise strategy resulted in more active therapy for
patients with sepsis, especially in early fluid resuscitation.
Stepwise target setting lactate kinetics in our goal-
directed therapy protocol could not only promote resus-
citation, but it could also prevent overtreatment. As we
know, despite full resuscitation, improvement in tissue
perfusion requires a certain length of time. Lactate
kinetics of 30% might be reasonable for early 6-h re-
suscitation, but for a shorter time, such as 2 or 4 h,
it might be too high and could lead to overtreatment.
Therefore, the targets of lactate kinetics were set at
10%, 20%, and 30% at 2 h, 4 h, and 6 h, respectively,
in our study to ensure that the targets could promote
therapy during various stages of resuscitation and that
overtreatment could be avoided at full steam. Serial
blood lactate levels reflect both lactate production and
clearance [26, 27]. We could see that the lactate kinetics
group achieved the more active therapy strategy, including
more fluid infusion at 4 h, 12 h and 24 h, but there were
no significant differences in the CVP levels, the ratio of
applications, or the dosage of vasoactive and inotropic
drugs between the two groups. Furthermore, there was no
significant difference in fluid balance at 48 and 72 h be-
tween the two groups.
There were several limitations to this study. First, it
was a single-center study. A larger, more rigorous multi-
center study could further confirm our conclusions in
the future. Second, this study was a non-blinded, ran-
domized, controlled study. Therefore, this study used a
rigorous method of randomization, rigorous training and
inspection procedures to ensure that compliance with
each step was maintained at a relatively high level
(greater than 90%), thus minimizing the potential for er-
rors. Third, this study explored only patients with defin-
ite diagnoses of sepsis, but patients with potential shock
who were not diagnosed have not been studied. Early
identification and resuscitation in these patients could
also be a very critical topic in sepsis therapy. Fourth,
there were significant differences between recent trials
on EGDT and the Rivers trial. Patients were already resusci-
tated by some method (initial ScvO2 values or lactate values
were comparable to those values after hours of therapy in
the Rivers trial). The moment of starting resuscitation will
have different impacts on outcome, and also importantly,
the interpretation of several goals will be different.
Conclusions
In summary, stepwise lactate kinetics target-oriented
therapy could reduce mortality among patients with sep-
sis, compared with ScvO2-oriented protocolized therapy
(≥70%). Lactate kinetics could become one of the indica-
tors of resuscitation. However, it still requires large-scale
and multicenter clinical studies to verify our findings.
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